Cover Image
市場調查報告書

A型流感病毒 H3N2亞型感染疾病:開發中產品分析

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 369078
出版日期 內容資訊 英文 102 Pages
訂單完成後即時交付
價格
Back to Top
A型流感病毒 H3N2亞型感染疾病:開發中產品分析 Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016
出版日期: 2016年08月10日 內容資訊: 英文 102 Pages
簡介

H3N2感染疾病是由變種的流感病毒H3N2病毒所引起。症狀有咳嗽,喉嚨痛,鼻涕·鼻塞,發冷,噁心,嘔吐,或是腹瀉等。危險因子有年齡,氣喘和糖尿病,心臟病,免疫系統衰弱,神經系統或神經發達症狀等慢性內科疾病。治療有使用抗病毒藥物和抗生素。

本報告提供治療A型流感病毒 H3N2亞型感染疾病所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查結果。

簡介

  • 調查範圍

A型流感病毒 H3N2亞型感染疾病 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關研究中的產品

治療藥的開發企業

  • AbbVie Inc
  • AIMM Therapeutics B.V.
  • Aphios Corporation
  • Celltrion, Inc.
  • FluGen, Inc.
  • Glide Pharmaceutical Technologies Limited
  • ILiAD Biotechnologies, LLC
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Medicago Inc.
  • MedImmune, LLC
  • Mucosis B.V.
  • NanoViricides, Inc.
  • OPKO Health, Inc.
  • Sarepta Therapeutics, Inc.
  • 武田藥品工業
  • VBI Vaccines Inc.
  • Visterra, Inc.
  • Zydus Cadila Healthcare Limited

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

目錄
Product Code: GMDHC8352IDB

Summary

Global Markets Direct's, 'Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016', provides an overview of the Influenza A Virus, H3N2 Subtype Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections
  • The report reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Influenza A Virus, H3N2 Subtype Infections therapeutics and enlists all their major and minor projects
  • The report assesses Influenza A Virus, H3N2 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Influenza A Virus, H3N2 Subtype Infections Overview
  • Therapeutics Development
    • Pipeline Products for Influenza A Virus, H3N2 Subtype Infections - Overview
    • Pipeline Products for Influenza A Virus, H3N2 Subtype Infections - Comparative Analysis
  • Influenza A Virus, H3N2 Subtype Infections - Therapeutics under Development by Companies
  • Influenza A Virus, H3N2 Subtype Infections - Therapeutics under Investigation by Universities/Institutes
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Influenza A Virus, H3N2 Subtype Infections - Products under Development by Companies
  • Influenza A Virus, H3N2 Subtype Infections - Products under Investigation by Universities/Institutes
  • Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • AIMM Therapeutics B.V.
    • Aphios Corporation
    • Celltrion, Inc.
    • FluGen, Inc.
    • Glide Pharmaceutical Technologies Limited
    • ILiAD Biotechnologies, LLC
    • Inovio Pharmaceuticals, Inc.
    • Johnson & Johnson
    • Medicago Inc.
    • MedImmune, LLC
    • Mucosis B.V.
    • NanoViricides, Inc.
    • OPKO Health, Inc.
    • Sarepta Therapeutics, Inc.
    • Takeda Pharmaceutical Company Limited
    • VBI Vaccines Inc.
    • Visterra, Inc.
    • Zydus Cadila Healthcare Limited
  • Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • APP-0205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APP-309 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Aspidasept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CR-8020 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CR-9114 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTP-27 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fluad (quadrivalent) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FluGEM - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gamma-Flu - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H3N2] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H3N2] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H3N2] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-872 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NEO-8877 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NVINF-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NVINF-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pertussis [strain BPZE1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PNSIA-28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • radavirsen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REDEE FLU - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for RSV and Influenza A Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VIS-410 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Influenza A Virus, H3N2 Subtype Infections - Dormant Projects
  • Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones
    • Featured News & Press Releases
      • Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season
      • Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100
      • Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2016
  • Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by AbbVie Inc, H2 2016
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by AIMM Therapeutics B.V., H2 2016
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Aphios Corporation, H2 2016
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Celltrion, Inc., H2 2016
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by FluGen, Inc., H2 2016
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Glide Pharmaceutical Technologies Limited, H2 2016
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by ILiAD Biotechnologies, LLC, H2 2016
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Johnson & Johnson, H2 2016
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Medicago Inc., H2 2016
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by MedImmune, LLC, H2 2016
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Mucosis B.V., H2 2016
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by NanoViricides, Inc., H2 2016
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by OPKO Health, Inc., H2 2016
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2016
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by VBI Vaccines Inc., H2 2016
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Visterra, Inc., H2 2016
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2016
  • Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top